Staphylococcus Aureus Bacteremia
28
7
8
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 29/100
7.1%
2 terminated out of 28 trials
83.3%
-3.2% vs benchmark
39%
11 trials in Phase 3/4
60%
6 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (28)
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Staphylococcus Aureus Network Adaptive Platform Trial
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Evaluating Simplified Layered Consent for Clinical Trials
Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia
Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia